lobbying_activities: 2960123
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2960123 | 75f68d6d-5516-4f19-b53e-985ec5632b18 | Q1 | AMERICAN SOCIETY OF ADDICTION MEDICINE | 401104864 | AMERICAN SOCIETY OF ADDICTION MEDICINE | 2023 | first_quarter | INS | Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives. Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free. Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024. Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose. Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD). | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 65000 | 0 | 0 | 2023-04-16T08:04:51-04:00 |